Drug manufacturers have been unable to validate significant clinical benefits of treatment for a
numerous of new compounds due to strict regulations. One of the significant trend observed in this
market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully
trying to bring about effective biomarker technologies to support and improve the drug development
process for potential drug candidates which is further expected to propel the demand.
Alzheimer’s Disease Diagnostic Market Covers the Table of Contents With Segments, Key Players And
Region. Based on Product Type, Alzheimer’s Disease Diagnostic Market is sub segmented into Genetic
testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging. On the Basis of Application,
Market is sub segmented into Clinics, Hospitals, Diagnostic Centers.
Major Players profiled in the Alzheimer’s Disease Diagnostic Market report incorporate: Eli Lilly, TauRx,
Alector, Accera, Treventis, Neuro-Bio, Cognition Therapeutics
Top Industry for Alzheimer’s Disease Diagnostic Market News
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly,
announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging
agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting
Alzheimer's disease diagnosis.
The study, referred to as A16, enrolled a total of 156 end-of-life patients with dementia, mild cognitive
impairment, or normal cognition who underwent flortaucipir PET imaging. Subsequently, 67 of these
patients were evaluated post-mortem. The study met pre-specified endpoints with flortaucipir
demonstrating statistically significant sensitivity and specificity for detecting tau pathology of Braak
Stage V/VI, a pathological staging scale for tau neurofibrillary tangles. Flortaucipir also demonstrated
statistically significant sensitivity and specificity for detecting a high level of total Alzheimer's disease
neuropathologic change (combining both tau and amyloid plaque densities), using the National Institute
on Aging and Alzheimer's Association (NIA-AA) neuropathology criteria.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/164023 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Alzheimer’s Disease Diagnostic in these regions, from 2014 to 2023
(forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Report contents include